// App-Quantinova.ai

POS0677 (2022) : CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • A. Rubbert-Roth

Principal Investigators

  • B. Combe

  • Z. Szekanecz

  • S. Hall

  • B. Haraoui

  • S. Attar

  • A. K. H. Ekwall

  • Y. Song

  • T. Shaw

  • O. Nagy

  • R. Xavier

Medical Centers

  • Cantonal Hospital St. Gallen, Rheumatology, St. Gallen, Switzerland

  • Montpellier University, Department of Rheumatology, Montpellier, France

  • University of Debrecen, Ophthalmology, Debrecen, Hungary

  • Deakin University, Melbourne, Australia

  • Institut de Rhumatologie de Montréal, Rheumatology, Montreal, Canada

  • King Abdulaziz University, Jeddah, Saudi Arabia

  • University of Gothenburg, Rheumatology, Gothenburg, Sweden

  • AbbVie Inc, Immunology, Illinois, United States of America

  • AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom

  • Universidade Federal do Rio Grande do Sul, Hospital de Clinicas of Porto Alegre, Porto Alegre, Brazil

Locations

  • Switzerland

  • France

  • Hungary

  • Australia

  • Canada

  • Saudi Arabia

  • Sweden

  • United States

  • United Kingdom

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved